We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Here's Why Investors Should Hold Green Dot (GDOT) Stock Now
Read MoreHide Full Article
A prudent investment decision involves buying stocks that have solid prospects and selling those that carry risks. At times, it is rational to hold certain stocks that have enough potential but are weighed down by tough market conditions. We believe Green Dot Corporation (GDOT - Free Report) is such a stock and investors should retain it in their portfolio.
Factors That Bode Well
Accelerated investments in both products and platform parts of its business have dampened the company’s short-term prospects but bode well for the mid to long-term.The stock, though down a massive 61.3% year to date, should recover when these investments start contributing to the company’s top and bottom lines.
Green Dot is investing an incremental $60 million this year in marketing new products and developing BaaS 3.0 and BaaS 4.0 technology platforms. This investment is expected to deliver incremental active accounts of more than one million and incremental revenues ranging between $200 million and $300 million by the end of 2019.
As a part of this investment, Green Dot recently launched Unlimited Cash Back Bank Account. It pays customers a 3% cash back bonus on online and in-app purchases. It comes with a free high-yield savings account that pays a 3% Annual Percentage Yield on their savings up to $10,000.
The company continues to improve and scale its operating infrastructure. Evidently, non-GAAP EPS and adjusted EBITDA increased 22% and 18%, respectively, in the second quarter of 2019.
The company continues to increase purchase volume and attract a more committed customer base. Its current BaaS platform programs are contributing significantly to GDV, active card and revenue growth.
Some better-ranked stocks in the broader Zacks Business Services sector include Fiserv , Booz Allen Hamilton (BAH - Free Report) and Charles River Associates (CRAI - Free Report) , each carrying a Zacks Rank #2 (Buy).
The long-term expected EPS (three to five years) growth rate for Fiserv, Booz Allen and Charles River is 12%, 13% and 13%, respectively.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better.
Image: Bigstock
Here's Why Investors Should Hold Green Dot (GDOT) Stock Now
A prudent investment decision involves buying stocks that have solid prospects and selling those that carry risks. At times, it is rational to hold certain stocks that have enough potential but are weighed down by tough market conditions. We believe Green Dot Corporation (GDOT - Free Report) is such a stock and investors should retain it in their portfolio.
Factors That Bode Well
Accelerated investments in both products and platform parts of its business have dampened the company’s short-term prospects but bode well for the mid to long-term.The stock, though down a massive 61.3% year to date, should recover when these investments start contributing to the company’s top and bottom lines.
Green Dot is investing an incremental $60 million this year in marketing new products and developing BaaS 3.0 and BaaS 4.0 technology platforms. This investment is expected to deliver incremental active accounts of more than one million and incremental revenues ranging between $200 million and $300 million by the end of 2019.
As a part of this investment, Green Dot recently launched Unlimited Cash Back Bank Account. It pays customers a 3% cash back bonus on online and in-app purchases. It comes with a free high-yield savings account that pays a 3% Annual Percentage Yield on their savings up to $10,000.
The company continues to improve and scale its operating infrastructure. Evidently, non-GAAP EPS and adjusted EBITDA increased 22% and 18%, respectively, in the second quarter of 2019.
The company continues to increase purchase volume and attract a more committed customer base. Its current BaaS platform programs are contributing significantly to GDV, active card and revenue growth.
Zacks Rank and Stocks to Consider
Green Dot currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Some better-ranked stocks in the broader Zacks Business Services sector include Fiserv , Booz Allen Hamilton (BAH - Free Report) and Charles River Associates (CRAI - Free Report) , each carrying a Zacks Rank #2 (Buy).
The long-term expected EPS (three to five years) growth rate for Fiserv, Booz Allen and Charles River is 12%, 13% and 13%, respectively.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better.
See these 7 breakthrough stocks now>>